<DOC>
	<DOCNO>NCT02318719</DOCNO>
	<brief_summary>Investigate efficacy safety DS-5565 subject Post-Herpetic Neuralgia ( PHN ) comparison placebo</brief_summary>
	<brief_title>DS-5565 Phase III Study Post-herpetic Neuralgia</brief_title>
	<detailed_description>[ Double Blind Phase ] The primary objective compare change Average Daily Pain Score ( ADPS ) baseline Week 14 Asian subject PHN receive DS-5565 versus placebo . [ Open Extension Phase ] The objective ass long-term safety efficacy DS-5565 subject PHN .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>PHN define pain present 3 month herpes zoster skin rash screening At screening , pain scale â‰¥ 40 mm Previous use neurolytic block</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Post-Herpetic Neuralgia</keyword>
</DOC>